Q-VD(OMe)-OPh: Broad-Spectrum Pan-Caspase Inhibitor for Apoptosis Control

Executive Summary: Q-VD(OMe)-OPh (quinolyl-valyl-O-methylaspartyl-[-2,6-difluorophenoxy]-methyl ketone) is a broad-spectrum, irreversible pan-caspase inhibitor that suppresses apoptosis with nanomolar potency and minimal cytotoxicity [APExBIO]. It inhibits caspases 1, 3, 8, and 9 with IC₅₀ values of 25–400 nM under cell-based and in vitro conditions [Mechanism overview]. Unlike legacy inhibitors such as Z-VAD-FMK, Q-VD(OMe)-OPh is non-toxic at high concentrations and suitable for long-term studies [Mu et al., 2023]. The compound is stable when stored as a solid at –20°C and is highly soluble in DMSO and ethanol. In animal models, intraperitoneal administration provides neuroprotection after ischemic stroke and reduces post-stroke complications [Preclinical data].

Biological Rationale

Apoptosis is a regulated form of programmed cell death essential for tissue homeostasis and development. Caspases, a family of cysteine proteases, orchestrate the execution phase of apoptosis via proteolytic cleavage of cellular substrates. Dysregulated apoptosis underlies diverse pathologies including cancer, neurodegeneration, and ischemic injury. Pan-caspase inhibitors have become indispensable tools for dissecting apoptotic pathways and for developing therapeutic strategies that target programmed cell death (see comparative review). Q-VD(OMe)-OPh is optimized for broad-spectrum caspase inhibition, overcoming the toxicity and selectivity limitations of earlier inhibitors such as Z-VAD-FMK and Boc-D-FMK [Mechanism overview]. This compound enables precise modulation of apoptosis in both cell culture and animal models, facilitating research into caspase signaling, cancer biology, and neuroprotection.

Mechanism of Action of Q-VD(OMe)-OPh

Q-VD(OMe)-OPh acts as an irreversible pan-caspase inhibitor by covalently binding to the active site cysteine of caspases. The molecule contains a quinolyl-valyl-O-methylaspartyl core and a 2,6-difluorophenoxy-methyl ketone warhead, enabling broad-spectrum inhibition with high specificity [product details]. The inhibitor blocks the proteolytic activity of key executioner caspases (caspase-3, -8, -9) and inflammatory caspase-1. Inhibition occurs rapidly, with IC₅₀ values ranging from 25 nM (caspase-3) to 400 nM (caspase-1) under standardized assay conditions (pH 7.4, 37°C, recombinant protein). Q-VD(OMe)-OPh does not display significant off-target effects at concentrations up to 100 μM in cell viability assays. The compound is insoluble in water but achieves >26 mg/mL solubility in DMSO and >97 mg/mL in ethanol, allowing for flexible formulation in research workflows. For storage, the solid form remains stable at –20°C, and solutions should be prepared fresh for short-term experimental use.

Evidence & Benchmarks

• Q-VD(OMe)-OPh inhibits recombinant caspases 1, 3, 8, and 9 with IC₅₀ values of 25–400 nM (buffer: pH 7.4, 25°C) [APExBIO].
• Demonstrates complete suppression of apoptosis in human cancer cell lines within 2–4 h at 10 μM concentration, outperforming Z-VAD-FMK and Boc-D-FMK [Benchmarking report].
• Shows minimal cytotoxicity at concentrations up to 100 μM in primary neuronal and fibroblast cultures over 72 h [Cellular toxicity study].
• Enhances AML blast differentiation when combined with differentiation-inducing agents in vitro (DMEM, 10% FBS, 37°C, 24–72 h) [Mu et al., 2023].
• Intraperitoneal administration (5–20 mg/kg) in murine models of ischemic stroke reduces brain infarct volume, decreases post-stroke bacteremia, and improves survival rates [Preclinical efficacy].
• Effective in apoptosis blockade during co-treatment experiments in colorectal cancer cell lines (DLD-1, HT29, Caco-2-CR) [Mu et al., Figure 4].

Applications, Limits & Misconceptions

Q-VD(OMe)-OPh is a versatile tool for apoptosis research, cancer biology, and neuroprotection studies. It is especially valuable for:

• Inhibition of caspase-dependent apoptosis in cell-based assays.
• Enhancement of differentiation in acute myeloid leukemia (AML) blast cultures.
• Neuroprotection in animal models of ischemic stroke via post-injury administration.
• Dissecting caspase signaling and programmed cell death mechanisms in cancer, including drug resistance models [Mu et al., 2023].

This article extends findings from "Q-VD(OMe)-OPh: Precision Pan-Caspase Inhibition for Advanced Research" by providing updated in vivo benchmarks and detailed solubility/handling data for translational workflows. For a mechanistic overview, see "Broad-Spectrum Pan-Caspase Inhibitor for Apoptosis & Signaling Pathways"; our review clarifies neuroprotection and AML applications. This page also updates and contrasts with "Q-VD(OMe)-OPh: Specificity and Performance Benchmarks" by including preclinical stroke research and AML differentiation use cases.

Common Pitfalls or Misconceptions

• Not effective in water-based solutions: Q-VD(OMe)-OPh is insoluble in water and requires DMSO or ethanol for stock preparation.
• Does not inhibit non-caspase proteases: The compound is caspase-specific and does not block other protease families (e.g., calpains, cathepsins).
• Not suitable for chronic in vivo use without formulation optimization: Long-term systemic administration may require specialized delivery vehicles to avoid precipitation and ensure bioavailability.
• Does not reverse established cell death: Q-VD(OMe)-OPh prevents apoptosis initiation but does not rescue cells already committed to death pathways.
• Not a substitute for genetic manipulation: Chemical inhibition complements but does not replace knockout/knockdown studies of caspase genes.

Workflow Integration & Parameters

For cell culture applications, Q-VD(OMe)-OPh is typically prepared as a 10–50 mM stock solution in DMSO. Working concentrations range from 1 to 20 μM, depending on cell type and assay sensitivity. Stocks should be stored at –20°C and used within 2–3 weeks for optimal stability. For animal studies, intraperitoneal doses of 5–20 mg/kg have demonstrated efficacy in murine ischemia and cancer models, with administration timed post-injury or pre-treatment as per experimental design [Stroke model protocols]. APExBIO recommends using freshly prepared solutions and monitoring for precipitation when diluting into aqueous buffers. The compound is provided as a solid (SKU: A8165) to ensure maximum shelf-life and reproducibility. For ordering and detailed specifications, see the Q-VD(OMe)-OPh product page at APExBIO.

Conclusion & Outlook

Q-VD(OMe)-OPh provides precise, broad-spectrum caspase inhibition with minimal toxicity, outperforming legacy inhibitors in both cell-based and animal studies. Its robust activity profile and favorable handling characteristics make it an essential tool for apoptosis research, cancer resistance studies, and neuroprotection models. As research advances, Q-VD(OMe)-OPh will continue to facilitate mechanistic insight into caspase signaling and the development of targeted therapeutic strategies. For extended applications and strategic deployment guidance, see also "Redefining Cell Death Modulation: Strategic Use of Q-VD(OMe)-OPh", which discusses its role in translational research beyond standard apoptosis assays.